rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ALMS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Alumis (ALMS) Stock Fair Value Moves Lower After Mixed Analyst Views On LUMUS

      Alumis now carries an updated fair value estimate of US$27.38, down from US$32.13, which reflects about a 15% reset in the price target. This change lines up with a split in recent analyst commentary after the LUMUS systemic lupus erythematosus study, with some focusing on execution risks and others pointing to potential in psoriasis and neurology. As you read on, you will see how this revised target fits into the broader, evolving Alumis story and how to track it over time. Stay updated as...

      Nov 16Yahoo FinanceALMS
      Alumis (ALMS) Faces Pressure After Clinical Results
      Nov 12Yahoo FinanceALMS
      InvestingPro Fair Value flagged Alumis as overvalued before 46% fall By Investing.com
      Oct 21Investing.comALMS
      Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
      Oct 9Yahoo FinanceALMS
      Alumis presents new psoriasis drug data, plans late 2026 filing
      Oct 9Investing.comALMS
      Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral Therapy
      Oct 9Yahoo FinanceALMS
      H.C. Wainwright reiterates Alumis stock rating on TYK2 data
      Oct 5Investing.comALMS
      Cantor Fitzgerald reiterates Alumis stock rating on oral therapy outlook
      Sep 16Investing.comALMS
      Alumis at Morgan Stanley conference: psoriasis data lifts outlook
      Sep 14Investing.comALMSMS
      Why is Alumis stock rallying today?
      Sep 10Investing.comALMS
      Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)

      Detailed price information for Alumis Inc (ALMS-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailALMS
      Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing

      Srinivas Akkaraju, Director, on September 04, 2026, executed a purchase for 986,721 shares in Alumis

      Sep 10Yahoo FinanceALMS
      Alumis at Cantor conference: psoriasis strength, lupus setback
      Sep 10Investing.comALMS
      Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares
      Sep 10Investing.comALMS
      Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

      Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. Envudeucitinib is an investigational oral inhibitor of tyrosine kinase 2, or TYK2. The primary endpoint was the British Isles Lupus Assessment Group-based Composite Lupus Assessment, […]

      Sep 9Yahoo FinanceALMS
      Alumis at Wells Fargo conference: lupus setback sharpens strategy
      Sep 8Investing.comALMSWFC
      Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow (NASDAQ:ALMS) 2026-09-04
      Sep 4Seeking AlphaALMS
      Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)

      Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

      Sep 4The Globe and MailALMSNVST
      Is Alumis (ALMS) Overvalued After Its 121% One Year Return?

      Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest. After a very strong 1 year return, the company now screens as expensive on the wider metrics, even after a steep pullback following mixed trial news. Alumis has delivered a 121.2% return over the past year, which puts extra focus on whether the current price already reflects much of the good news investors expect. The recent Phase 2b LUMUS trial setback in lupus, together with...

      Sep 3Yahoo FinanceALMS
      Alumis stock downgraded at Guggenheim (ALMS:NASDAQ)
      Sep 3Seeking AlphaALMS
      Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy

      In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorable safety profile over 48 weeks. An important finding was that a prespecified subgroup of patients with a high interferon gene signature showed robust clinical responses, supporting Alumis’ plan to pursue biomarker-driven Phase 3 development and an NDA in...

      Sep 3Yahoo FinanceALMS
      Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?

      Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial readout has gone hand in hand with sharp share price volatility, with a 7 day share price return of down 56.18% and a 30 day share price return of down 60.38%. Alumis still shows a year to date share price return of 15.58% and a 1 year total...

      Sep 3Yahoo FinanceALMS
      Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints

      Alumis (NasdaqGS: ALMS) reported that its lead drug envudeucitinib did not meet primary or secondary endpoints in a Phase 2b lupus trial. The company highlighted strong efficacy and safety signals in a genetically defined IFNGS high subgroup of lupus patients within the study. Alumis plans to continue developing envudeucitinib and discuss potential regulatory paths for broader immune mediated indications based on the subgroup data. This update on Alumis shows how targeted drug development...

      Sep 3Yahoo FinanceALMS
      Guggenheim Downgrades Alumis to Neutral From Buy
      Sep 3Yahoo FinanceALMS
      Guggenheim downgrades Alumis stock rating after trial miss
      Sep 2Investing.comALMS
      Alumis (ALMS): Broken Story, Unbroken Asset, Buying A De-Risked Psoriasis Franchise At A Lupus Panic Price
      Sep 2Seeking AlphaALMS
      This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
      Sep 2BenzingaALMSOGE
      Morgan Stanley cuts Alumis stock price target on lupus trial failure
      Sep 2Investing.comALMS
      Wells Fargo cuts Alumis stock price target on SLE trial results
      Sep 2Investing.comALMS
      HC Wainwright Upgrades Alumis to Buy From Neutral, Adjusts Price Target to $15 From $25

      Alumis (ALMS) has an average rating of buy and mean price target of $31.44, according to analysts po

      Sep 2Yahoo FinanceALMS
      Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating

      Alumis (ALMS) has an average rating of buy and mean price target of $31.44, according to analysts po

      Sep 2Yahoo FinanceALMS
      ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?

      The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.

      Sep 1Yahoo FinanceALMS
      Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS)

      Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.

      Sep 1Seeking AlphaALMS
      Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market
      Sep 1Barron'sAAPLALMSHOODMRVLNVDATSLADELLMDTNVS
      A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It
      Sep 1Barron'sALMS
      Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise

      Alumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients wi

      Sep 1Yahoo FinanceALMS
      Why Is Alumis Stock Falling Tuesday?
      Sep 1BenzingaALMS
      Alumis falls after mid-stage trial setback for lead drug
      Sep 1Seeking AlphaALMS
      Alumis Phase 2b lupus trial misses primary and secondary endpoints

      Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary or secondary endpoints in the overall study population.

      Sep 1Yahoo FinanceALMS
      Alumis stock tumbles 55% after lupus drug trial misses goals
      Sep 1Investing.comALMS
      Why is Alumis stock collapsing today?
      Sep 1Investing.comALMS
      Top Midday Decliners

      Alumis (ALMS) said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-

      Sep 1Yahoo FinanceALMS
      Alumis’ TYK2 drug fails in key lupus study

      Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

      Sep 1Yahoo FinanceALMS

      This is the newest page. Registered accounts read further back.